Phenotypes and serum level of alpha-1-antitrypsin in lung cancer

Journal of B.U.ON.

Volumn 16, Issue 4, 2011, Pages 672-676

  Topic, Aleksandra ^a   Ljujic, M ^a   Petrovic Stanojevic, N ^b   Dopudja Pantic, V ^b   Radojkovic, D ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b ZVEZDARA UNIVERSITY MEDICAL CENTER   (Serbia)

Author keywords

Alpha 1 antitrypsin; Lung cancer; Polymorphism; Serum level

Indexed keywords

ALPHA 1 ANTITRYPSIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CASE CONTROL STUDY; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC RISK; HUMAN; ISOELECTRIC FOCUSING; LUNG CANCER; LUNG EMPHYSEMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; PHENOTYPE; PROTEIN FUNCTION; RISK FACTOR;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; SMALL CELL LUNG CARCINOMA;

EID: 84855433345     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. American Thoracic Society/European Respiratory Society Statement: Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency. Am J Respir Crit Care Med 2003; 168: 818-900.
2. Greene CM, Miller SD, Carroll TP et al. Anti-apoptotic effects of Z alpha1 -antitrypsin in human bronchial epithelial cells. Eur Respir J 2010; 35: 1155-1163.
3. Pott GB, Chan ED, Dinarello CA, Shapiro L. α-1-Antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J Leukoc Biol 2009; 85: 886-895.
4. Kloth JN, Gorter A, Fleuren GJ et al. Elevated expression of SerpinA1 and SerpinA3 in HLA-positive cervical carcinoma. J Pathol 2008; 215: 222-230. (Pubitemid 351956703)
5. Duplantier MM, Lamant L, Sabourdy F, De Reynies G, Espinos E. Serpin A1 is overexpressed in ALK+ anaplastic large cell lymphoma and its expression correlates with extranodal dissemination. Leukemia 2006; 20: 1848-1854. (Pubitemid 44574995)
6. Higashtyama M, Dot O, Kodama K, Yokouchi H, Tateishi R. An evaluation of the prognostic significance of alpha-1-antitrypsin expression in adenocarcinomas of the lung: an immunohistochemical analysis. Br J Cancer 1992; 65: 300-302.
7. Boskovic G, Twining SS. Local control of alpha 1-proteinase inhibitor levels: regulation of alpha1-proteinase inhibitor in the human cornea by growth factors and cytokines. Biochim Biophys Acta 1998; 1403: 37-46. (Pubitemid 28288280)
8. Topic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Spasic S. Association of moderate alpha-1-antitrypsin deficiency with lung cancer in the Serbian population. Arch Med Res 2006; 37: 866-870. (Pubitemid 44404116)
9. El-Akawi ZJ, Sawalha DH, Nusier MK. Alpha-1 antitrypsin genotypes in breast cancer patients. J Health Sci 2008; 54: 493-496.
10. El-Akawi ZJ, Al-Hindawi FK. Alpha-1 antitrypsin phenotypes in patients with lung, prostate and breast cancer. Saudi Med J 2004; 25: 186-189. (Pubitemid 38279355)
11. 1-antitrypsin (α1-AT) in patients with lung cancer in Harbin. Zhongguo Fei Ai Za Zhi 2001; 4: 327-329.
12. Sehested M, Hirsch FR, Hou-Jensen K, Hansen HH. Histological examination for Z-gene alpha1-antitrypsin deficiency in small cell anaplastic carcinoma of the lung. Eur J Respir Dis 1981; 62: 107-110. (Pubitemid 11153204)
13. Yang P, Sun Z, Krowka MJ et al. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med 2008; 168: 1097-1103. (Pubitemid 351749227)
14. Yang P, Bamlet WR, Sun Z et al. Alpha1-antitrypsin and neutrophil elastase imbalance and lung cancer risk. Chest 2005; 128: 445-452. (Pubitemid 40994509)
15. Yang P, Wentzlaff KA, Katzmann JA et al. Alpha1-antitrypsin deficiency allele carriers among lung cancer patients. Cancer Epidemiol Biomarkers Prev 1999; 8: 461-465. (Pubitemid 29230552)
16. De Serres FJ, Blanco I, Fernández-Bustillo E. PIS and PI Z alpha-1 antitrypsin deficiency worldwide. A review of existing genetic epidemiological data. Monaldi Arch Chest Dis 2007; 67: 184-208. (Pubitemid 351188320)
17. Topic A, Ljujic M, Nikolic A et al. Alpha-1-antitrypsin Phenotypes and Neutrophil Elastase Gene Promoter Polymorphisms in Lung Cancer. Pathol Oncol Res 2011; 17: 75-80.
18. El-Akawi ZJ, Abu-Awad AM, Sharara AM, Khader Y. The importance of alpha-1 antitrypsin (alpha1-AT) and neopterin serum levels in the evaluation of non-small cell lung and prostate cancer patients. Neuro Endocrinol Lett 2010; 31: 113-116.
19. El-Akawi ZJ, Al-Hindawi FK, Bashir NA. Alpha-1 antitrypsin (alpha1-AT) plasma levels in lung, prostate and breast cancer patients. Neuro Endocrinol Lett 2008; 29: 482-484.
20. Zelvyte I, Wallmark A, Piitulainen E, Westin U, Janciauskiene S. Increased plasma levels of serine proteinase inhibitors in lung cancer patients. Anticancer Res 2004; 24: 241-247. (Pubitemid 38279714)
21. Harris CC, Cohen MH, Connor R, Primack A, Saccomanno G, Talamo RC. Serum alpha 1-antitrypsin in patients with lung cancer or abnormal sputum cytology. Cancer 1976; 38: 1655-1657.
22. Dabrowska M, Prokopowicz J, Kemona H, Kretowska J, Kiluk S, Gluszczak M. Serum concentration of alpha-2-macroglobulin, alpha-1-antitrypsin and alpha-2-antichymotrypsin in patients with lung carcinoma. Folia Haematol Int Mag Klin Morphol Blutforsch 1988; 115: 817-823.
23. Micksche M, Kokron O. Serum levels of alpha1-antitrypsin and alpha2-macroglobulin in lung cancer. Osterr Z Onkol 1977; 3: 116-119.
24. Varela AS, López Sáez JJ. Utility of plasmatic levels of alpha1-antiprotease (A1AP) as a cancer marker. Cancer Lett 1995; 89: 15-21.